Catalog No.S1455 Synonyms: SB-207499
Molecular Weight(MW): 343.42
Cilomilast is a potent PDE4 inhibitor with IC50 of about 110 nM, has anti-inflammatory activity and low central nervous system activity. Phase 3.
Cited by 6 Publications
4 Customer Reviews
LNCaP-C4 prostate cancer cells were suspended in matrigel and transplanted under the kidney capsule of male nude mice hosts. Mice were treated with vehicle-only (10% EtOH, 90% olive oil) control, cilomilast or NVP-ABE171 by gavage (n=7-11 for each respective group)The xenografts LNCaP-C4 xenografts were excised, fixed in formalin, and embedded in paraffin blocks. IHC with Ki67 (proliferation), TUNEL (apoptosis), or p21 (senescence) was performed. Representative Ki67 and TUNEL photomicrographs for cilomilast and NVP-ABE171 treatment group are shown.
Mol Cancer Res 2014 10.1158/1541-7786.MCR-14-0110. Cilomilast purchased from Selleck.ALP activity levels relative to control: (a) samples treated with 300 ng/mL of BMP-2; (b) samples treated with 30 ng/mL of BMP-2. Cells cultured with 1% DMSO for 11 days were used as control cells. Bar represent mean SD for 8 experiments. PDE4 I =PDE4 inhibitor, SM =standard medium, OM =osteogenic medium.
Biochimie 2012 94, 2360e2365 . Cilomilast purchased from Selleck.
ALP activity levels relative to samples treated with DMSO. Cells cultured with1% DMSO for 11 days were used as control cells. The inset shows a schematic representation of the PDE4 inhibitor (PDE4 I) and H89 pathways. PDE4 I blocks thedegradation of the intracellular cAMP signalling by PDE, and increases the PKA levels. By the use of an efficient PKA inhibitor, H89, the pathway activated downstream by PKA is completely blocked. Bar represent mean SD for 8 experiments.
Biochimie 2012 94, 2360e2365 . Cilomilast purchased from Selleck.
Phosphodiesterase (PDE) 4 inhibitors increase formoterol-induced cAMP and MKP-1 mRNA expression. Growth-arrested ASM cells were pretreated for 30 minutes with the PDE4 inhibitors cilomilast (A and B, 0.1-10 μM). The impact of PDE4 inhibition was assessed by: (A) measuring cAMP production in response to stimulation with 10 nM formoterol for 15 minutes in comparison to vehicle (results expressed as percentage of formoterol-induced cAMP); and (B) measuring MKP-1 mRNA expression by RT-PCR in response to stimulation with 10 nM formoterol for 1 hour in comparison to vehicle (results expressed as percentage of formoterol-induced MKP-1). Statistical analysis was performed using one-way ANOVA then Fisher’s post hoc multiple comparison test. *Significant increase (P < 0.05). Data are mean ± SEM values from n = 7 primary ASM cell cultures.
Am J Respir Cell Mol Biol, 2015, 52(5):634-40. Cilomilast purchased from Selleck.
Purity & Quality Control
Choose Selective PDE Inhibitors
|Description||Cilomilast is a potent PDE4 inhibitor with IC50 of about 110 nM, has anti-inflammatory activity and low central nervous system activity. Phase 3.|
|Features||Cilomilast has been used to treat chronic obstructive pulmonary disease (COPD) for many years.|
Cilomilast produces a concentration-dependent increase in cAMP content in U937 cells. Cilomilast produces a concentration-dependent increase in cAMP content in U937 cells.  In isolated human monocytes, Cilomilast and (R)-rolipram are equipotent at suppressing LPS-induced TNF-α formation with -log (IC50) of 7.0 and 7.2, respectively. Both Cilomilast and (R)-rolipram produces a modest prevention of fMLP-induced degranulation of human neutrophils. Cilomilast and (R)-rolipram are equipotent at suppressing neutrophil activation with -log (IC50) of 7.1 and 6.4, respectively.  Cilomilast significantly decreases the expression of TNF-α in the cornea and IL-1α, IL-1β, and TNF-α in the conjunctivaas compared to vehicle control. Cilomilast treatment markedly decreases the presence of CD11b+ antigen-presenting cells in the central and peripheral cornea, and leads to decreased conjunctival expression of cytokines IL-6, IL-23, and IL-17. Moreover, Cilomilast decreases the expression of IL-17 and IL-23 in the draining lymph nodes.  Cilomilast reduces TLR4 expression, IL-8 release and neutrophil chemotactic activity as well as it increased IP-10 release and lymphocyte chemotactic activity. 
|In vivo||Cilomilast inhibits human TNFα production with oral ED50 of 4.9 mg/kg. In contrast to their equipotent activity against TNFα production, Cilomilast (ED50 = 2.3 mg/kg, p.o.) is 10-fold less potent than R-rolipram (ED50 = 0.23 mg/kg, p.o.) in reversing reserpine-induced hypothermia, a model of antidepressant activity.  In time course studies, Cilomilast (30 mg/kg, p.o.) suppresses TNFα production for at least 10 hour. The ability of Cilomilast to modulate interleukin-4 productionin vivo is assessed in a chronic oxazolone-induced contact sensitivity model in Balb/c mice. Topical administration of Cilomilast (1000 μg) inhibits intralesional concentrations of interleukin-4.  Orally administered cilomilast dose-dependently inhibits production of interleukin-4, TNF-α, and cysteinyl leukotrienes, as well as leukocyte infiltration in bronchoalveolar lavage fluid from the airways of ovalbumin-sensitized Brown Norway rats .|
-  Griswold DE,et al. J Pharmacol Exp Ther. 1998, 287(2),705-711.
-  Barnette MS, et al. J Pharmacol Exp Ther. 1998, 284(1), 420-426.
-  Sadrai Z, et al. Invest Ophthalmol Vis Sci. 2012.
|In vitro||DMSO||69 mg/mL (200.92 mM)|
|Ethanol||50 mg/mL (145.59 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+95% Corn oil
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.